Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421589 · ClinicalTrials.gov registry record · NA
Growth Hormone Treatment on Phosphocreatine Recovery in Obesity
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT01421589: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01421589 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01421589, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
Obesity is associated with reduced growth hormone (GH) secretion. Reduced GH secretion in obesity is associated with increased cardiovascular disease risk. However, it is not yet known how reduced GH increases cardiovascular disease risk in obesity. The investigators hypothesize that reduced GH contributes to dysfunction of the mitochondria. Therefore, the investigators hypothesize that treatment of obese subjects with reduced GH secretion with GH will improve mitochondrial function and that this improvement in mitochondrial function will contribute, in part, to the effects of GH to improve metabolic parameters in obesity. The investigators propose to study skeletal muscle mitochondria in obese subjects with reduced GH secretion using magnetic resonance spectroscopy and muscle biopsies before and after treatment with GH.
Interventions
- DRUG Growth hormone treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01421589
The ClinicalTrials.gov registry entry for NCT01421589 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Growth hormone treatment is the first listed.
NCT01421589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01421589 about?
NCT01421589 is a clinical study titled "Growth Hormone Treatment on Phosphocreatine Recovery in Obesity". Obesity is associated with reduced growth hormone (GH) secretion. Reduced GH secretion in obesity is associated with increased cardiovascular disease risk. However, it is not yet known how reduced GH increases cardiovascular disease risk in obesity. The investigators hypothesize that reduced GH cont...
What is the current status of trial NCT01421589?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2011-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01421589?
The interventions under investigation include: Growth hormone treatment (DRUG).
Who is sponsoring clinical trial NCT01421589?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.